Popular Trials
Kinase Inhibitor
Sorafenib for Hepatocellular Carcinoma
Recruiting2 awardsPhase 2
Berkeley, California
This trial is testing if VT-122, a combination of two drugs, can help patients with advanced liver cancer who have severe symptoms. The goal is to see if it can reduce inflammation and improve their ability to handle their main cancer treatment, possibly leading to better health and longer life.
Bcl-2 Inhibitor
Navitoclax + Sorafenib for Cancer
Recruiting1 awardPhase 1
Scottsdale, Arizona
This trial is testing navitoclax and sorafenib tosylate in patients whose solid tumors have returned or don't respond to treatment. The drugs aim to stop cancer growth by blocking essential enzymes. Sorafenib has shown effectiveness in several cancers. The study will determine the best dose and monitor side effects.
mTOR Inhibitor
Everolimus +5 More for Pediatric Brain Tumor
Recruiting3 awards10 criteria
Seattle, Washington
This research study is a Feasibility clinical trial. In this trial, researchers are trying to figure out whether a medication can be chosen based on rapid testing done on tumor tissue. Information from a feasibility or pilot trial will hopefully help researchers plan larger trials in the future to determine the effect of this therapy.
Proton Beam Therapy
Multimodal Therapy for Rhabdomyosarcoma
Recruiting1 awardPhase 2
Jacksonville, Florida
This trial will treat people with newly diagnosed rhabdomyosarcoma with different intensities of chemotherapy, radiation and surgery based on how high-risk the cancer is. For the intermediate and high risk patients, they will receive an additional 12 weeks of maintenance therapy with anti-angiogenic chemotherapy.
Popular Filters
Phase 3 Trials
Checkpoint Inhibitor
Immunotherapy for Liver Cancer
Recruiting2 awardsPhase 3
Los Angeles, California
This trial is testing whether two immunotherapy drugs or one immunotherapy drug is better than the standard-of-care drug for people with liver cancer that can't be removed by surgery and who haven't gotten any other systemic therapy.
Checkpoint Inhibitor
Nivolumab + Ipilimumab for Liver Cancer
Recruiting2 awardsPhase 3
Tucson, Arizona
This trial is testing a combination of two drugs, nivolumab and ipilimumab, which help the immune system fight cancer. It targets patients with advanced liver cancer who haven't received any previous whole-body treatments. The goal is to see if these drugs can help patients live longer compared to standard treatments. Nivolumab and ipilimumab have been used in combination to treat various advanced cancers, showing promising results but with higher side effects compared to using a single drug.
Trials With No Placebo
Kinase Inhibitor
Everolimus + Sorafenib for Thyroid Cancer
Recruiting1 awardPhase 2
Basking Ridge, New Jersey
This trial is testing a combination of two pills, sorafenib and everolimus, to treat thyroid cancer. Sorafenib cuts off the tumor's blood supply, while everolimus blocks a protein that helps cancer cells grow. Everolimus is approved for various cancers, including breast cancer, and has shown promise in combination therapies. The study aims to see if this combination works better than current treatments.
Tyrosine Kinase Inhibitor
Sorafenib +1 More for Breast Cancer
Recruiting3 awardsPhase 1 & 2
Montreal, Quebec
This is a phase IB/II trial of sorafenib, a new tyrosine kinase inhibition of multiple genes that is active against renal cancer, plus vinorelbine, a chemotherapy agent active in breast cancer. The investigators are combining these 2 drugs in order to determine if the investigators can increase the activity of vinorelbine in metastatic breast cancer patients. Patients with measurable metastatic breast cancer without previous chemotherapy for metastatic disease are eligible for the protocol. They will be treated with 2 different dose levels of sorafenib in order to determine the most tolerable dose.
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.